Clinical evaluation of Paclitaxel and Carboplatin combination chemotherapy plus intensity-modulated radiotherapy for elderly patients with advanced cervical cancer
10.3760/cma.j.issn.0254-9026.2021.01.014
- VernacularTitle:紫杉醇联合卡铂化疗同期调强适形放疗在老年晚期宫颈癌患者中的应用
- Author:
Jie HOU
;
Tianyong ZHAO
;
Qinlu BAO
- From:
Chinese Journal of Geriatrics
2021;40(1):92-95
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical effects of Paclitaxel and Carboplatin combination chemotherapy with concurrent intensity-modulated radiotherapy for elderly patients with advanced cervical cancer.Methods:From February 2107 to July 2018, 82 patients with advanced cervical cancer were enrolled from our hospital.According to the treatment plan, they were divided into the observation group(patients with Paclitaxel/Carboplatin chemotherapy + concurrent intensity-modulated radiation therapy)and the control group(patients with conventional chemotherapy). Clinical effects and the occurrence of toxic and side effects were evaluated and analyzed for the two groups.Results:The overall rate of effectiveness for the observation group was 92.7%, which was higher than that for the control group(75.6%), and the difference was statistically significant( χ2=4.479, P=0.034). The tumor metastasis rate was lower in the observation group than in the control group(2.4% vs.14.6%, χ2=3.905, P=0.048). The incidence of gastrointestinal side effects > grade Ⅲ was lower in the observation group than in the control group(8.1% vs.45.5%, χ2=12.736, P=0.000). Conclusions:Paclitaxel and Carboplatin plus intensity-modulated radiotherapy for elderly patients with advanced cervical cancer can help keep tumor size under control, reduce the risk of toxic and side effects during treatment, alleviate patient suffering, and ensure a smooth treatment experience.
